Comparison of baseline characteristics between POLEmut, p53abn, and POLEmut-p53abn
| Characteristics | Molecular class | P value | Multiple comparisons P value | |||
| POLEmut (n=22) | p53abn (n=73) | POLEmut-p53abn (n=15) | POLEmut vs p53abn vs POLEmut-p53abn | POLEmut vs POLEmut-p53abn | p53abn vs POLEmut-p53abn | |
| Clinical and pathologic characteristics | ||||||
| Age at surgery (years), mean (SD) | 56.6 (11.0) | 66.7 (11.0) | 56.1 (10.9) | <0.001 | 1.000 | 0.003 |
| BMI (kg/m2), mean±SD | 26.0 (5.5) | 28.0 (6.4) | 23.6 (3.7) | 0.055 | 0.796 | 0.060 |
| Early vs advanced-stage, n (%) | <0.001 | 0.791 | 0.001 | |||
| Early (I–II) | 20 (90.9) | 34 (46.6) | 14 (93.3) | |||
| Advanced | 2 (9.1) | 39 (53.4) | 1 (6.7) | |||
| Endometrioid vs other, n (%) | <0.001 | 0.220 | 0.002 | |||
| Endometrioid | 22 (100.0) | 36 (50.0) | 14 (93.3) | |||
| Non-endometrioid | 0 | 36 (50.0) | 1 (6.7) | |||
| Missing | 0 | 1 | 0 | |||
| Grade, n (%) | <0.001 | 0.008 | 0.724 | |||
| G1–2 | 17 (77.3) | 21 (28.8) | 5 (33.3) | |||
| G3 | 5 (22.7) | 52 (71.2) | 10 (66.7) | |||
| Myometrial invasion, n (%) | 0.14 | – | – | |||
| None | 6 (27.3) | 10 (14.1) | 5 (33.3) | |||
| <50 | 12 (54.6) | 31 (43.7) | 5 (33.3) | |||
| ≥50 | 4 (18.2) | 30 (42.3) | 5 (33.3) | |||
| Unknown | 0 | 2 | 0 | |||
| LVSI, n (%) | 0.45 | – | – | |||
| Absent or focal | 18 (81.8) | 54 (79.4) | 14 (93.3) | |||
| Diffuse | 4 (18.2) | 14 (20.6) | 1 (6.7) | |||
| Missing | 0 | 5 | 0 | |||
| Lymph node metastases, n (%) | 0.11 | – | – | |||
| Negative | 21 (95.5) | 40 (75.5) | 13 (100.0) | |||
| ITC | 0 | 1 (1.9) | 0 | |||
| Micro/macro | 1 (4.6) | 12 (22.6) | 0 | |||
| Missing/unknown | 0 | 20 | 2 | |||
| Risk classification*, n (%) | <0.001 | 0.135 | 0.007 | |||
| Low | 15 (68.2) | 10 (13.7) | 5 (33.3) | |||
| Intermediate | 2 (9.1) | 8 (11.0) | 5 (33.3) | |||
| High-intermediate | 2 (9.09) | 8 (11.0) | 3 (20.0) | |||
| High | 3 (13.6) | 30 (41.1) | 2 (13.3) | |||
| Advanced/metastatic | 0 | 17 (23.3) | 0 | |||
| Molecular characteristics | ||||||
| p53 IHC, n (%) | – | <0.001 | ||||
| Aberrant | – | 64 (91.4) | 5 (41.7) | |||
| Subclonal | – | 2 (2.9) | 4 (33.3) | |||
| Wild-type expression | – | 4 (5.7) | 3 (25.0) | |||
| Missing | 3 | 3 | ||||
| TP53 NGS, n (%) | – | 0.840 | ||||
| Pathogenic | – | 67 (91.8) | 14 (93.3) | |||
| Wild type | – | 6 (8.2)† | 1 (6.7) | |||
* ESGO/ESTRO/ESP guidelines,2020 – molecular classification unknown.
†a case of VUS was considered as wild-type.
BMI, body mass index; ESGO, European Society of Gynaecological Oncology; ESP, European Society of Pathology; ESTRO, European Society for Radiotherapy and Oncology; IHC, immunohistochemistry; ITC, isolated tumor cells; LVSI, lymphovascular space invasion; NGS, next-generation sequencing; p53abn, p53 abnormal; POLEmut, POLE mutated; SD, standard deviation; VUS, variant of uncertain significance.